NCT Number: NCT02024035
Protocole Advanced RadioTherapy ORL
The purpose of this study is to do health economic evaluation of tomotherapy and dynamic arctherapy (2 techniques exist: RapidArc and Vmat).
This study evaluate also local disease control after 18 months in patients with an ENT epidermoid carcinoma and treated by tomotherapy orarctherapy .
The number of patients required in this study is: 300:
* Number of patients treated with tomotherapy: 120 * Number of patients treated with dynamic arctherapy RapidArc: 120 * Number of patients treated with dynamic arctherapy Vmat: 60
This is a prospective; multicentric and non randomized study.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Institut Sainte Catherine, Avignon, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- PS <= 2
- Age >= 18 years
- Histologically proven carcinoma
- Cavum Epidermoïd or undifferentiated carcinoma; or oropharynx epidermoïd carcinoma; or oral cavity epidermoïd carcinoma
- Stade T1 to T4
- M0
- Patient with no surgery ( except laser partial surgery and ganglionic cleaning out)
- Bilateral ganlionic cervical area irradiation
- Covered by a medical insurance.
Exclusion criteria
- Prior history of other malignancies in the last 5 years(except non evolutive ENT cancer or squamous cell carcinoma )
- Re-irradiation indication
- Unilateral cervical area irradiation
- Post-operative radiotherapy
- Patient treated by amifostine
- Impossible follow-up
Treatment and study plan
Primary outcomes
-
The various of cost between tomotherapy and Intensity Modulation Radiation Therapy (IMRT)
Time frame: 18 months
The purpose of this study is to realise a Health economic evaluation of the various cost between tomotherapy and Intensity Modulation Radiation Therapy (IMRT)
Secondary outcomes
-
The economic impact of the learning curve of the tomotherapy process, the operating procedures and the activity of the centres
Time frame: 18 months
To estimate the economic impact of the learning curve of the tomotherapy process, the operating procedures and the activity of the centres
-
To determine the difference of cost for the preparation phase and the irradiation phase of the radiotherapy procedure
Time frame: 18 months
One of the secondary objectives for the economic evaluation is to individualize the difference of cost for the preparation phase and the irradiation phase of the radiotherapy procedure
-
The salivary toxicity
Time frame: at 6; 12 and 18 months post treatment
The salivary function will be assessed at baeline; 6; 12 and 18 months post treatment.
This evaluation will be done with differents scale (RTOG, EVA); and with salivary scan.
-
To determine the rate of disease local control
Time frame: Baseline, Month 6; Month 18
Assement of disease by clinical exam and/or imaging.
Sponsors and collaborators
Lead sponsor
Centre Leon Berard
Other
Collaborators
- The Biostatistics and Therapy Evaluation Unit
Registry information
Official study title
Health Economic Evaluation of Tomotherapy and Dynamic Arctherapy in ENT Epidermoid Carcinoma
Acronym: ART-ORL
Important dates
- Study start
- 2009
- Primary completion
- 2012
- Study completion
- 2013
- First posted
- Dec 31, 2013
- Registry last updated
- Dec 31, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
NCT06307093
Carcinoma, Carcinoma, Squamous Cell
Istra, Moscow Oblast, Russia
View Trial DetailsA Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
NCT07435324
Carcinoma, Carcinoma, Squamous Cell
Arkhangelsk, Russia
View Trial DetailsA Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
NCT07435311
Carcinoma, Carcinoma, Squamous Cell
Barnaul, Russia
View Trial DetailsTaiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer Survivors
NCT07682285
Cancer-related Fatigue, Carcinoma
Taipei, Taiwan
View Trial Details